PBAC's latest decision on Budesonide + formoterol: Recommended with restriction (2019). Considered for Asthma in children aged <12 years who have failed PBS-subsidised fluticasone propionate and salmeterol as a fixed dose combination.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Children aged ≥6 years with asthma who have failed PBS-subsidised fluticasone propionate and salmeterol fixed dose combination therapy.
Therapy area
Respiratory
Line of therapy
Second-line
Evidence base
Registry
Economic model
Not modelled
Eligible patients/year
798
ICER note
This is not a new drug submission; it is a PBS restriction advisory item. No economic evaluation was performed.